This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Multicentre double-blind randomized controlled trial of perhexiline as a metabolic modulator to augment myocardial protection in patients with left ventricular hypertrophy undergoing cardiac surgery

Thursday, September 17, 2015

Submitted by


Source Name: Eur J Cardiothorac Surg


Eshan L. Senanayake, Neil J. Howell, Aaron M. Ranasinghe, Nigel E. Drury, Nick Freemantle, Michael Frenneaux, Tessa Oelofse, David Green, Ian C. Wilson, Stephen J. Rooney, Jorge Mascaro, Timothy R. Graham, Sunil Bhudia, Michael Lewis, and Domenico Pagano

Perhexilene modulates cardiac metabolism and is expected to provide myocardial protection during cardiac surgery in patients with left ventricular hypertrophy. The agent was tested in a randomized clinical trial and administered per os preoperatively. The primary endpoint was use of inotropics for low cardiac output. The trial was halted after analysis of 110 of 220 planned patients due to the lack of difference between the groups for the primary and also for secondary endpoints. 

Add comment

Log in or register to post comments